



Universiteit
Leiden
The Netherlands

Huntington's disease: cognition and apathy

Baake, V.

Citation

Baake, V. (2019, May 29). *Huntington's disease: cognition and apathy*. Retrieved from <https://hdl.handle.net/1887/74007>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/74007>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The following handle holds various files of this Leiden University dissertation:

<http://hdl.handle.net/1887/74007>

Author: Baake, V.

Title: Huntington's disease: cognition and apathy

Issue Date: 2019-05-29



Chapter 4

Influence of medication use on cognitive performance in Huntington's disease

Verena Baake^{1,2}, REGISTRY Investigators of the European Huntington's Disease Network³ and Raymund A.C. Roos¹

¹Leiden University Medical Center, Department of Neurology, Leiden, The Netherlands

² Huntington Center Topaz Overduin, Katwijk, The Netherlands

³Membership of the REGISTRY Investigators of the European Huntington's Disease Network is provided in the acknowledgments

Submitted

Abstract

Background: In Huntington’s disease (HD), cognitive decline starts early and continues as the disease progresses. As cognition is recognized as a potential clinical trial endpoint, it is essential to identify factors which can influence cognitive performance in HD. Medication treating non-cognitive neuropsychiatric disturbances and tetrabenazine, which are generally known to have a negative influence on cognition, are often prescribed in HD patients.

Objective: This study evaluates whether cognitive performance differs between users and non-users of these drugs at HD clinics throughout Europe.

Methods: In total, 2,289 participants of the REGISTRY study fulfilled the criteria for cognitive assessment and recorded medication use at their baseline visit. Participants were grouped according to disease stage and medication use: i.e. benzodiazepines, selective serotonin reuptake inhibitor (SSRI) antidepressants, antipsychotics, atypical antipsychotics and tetrabenazine. Univariate general linear model analysis was conducted.

Results: Medication use was common in the REGISTRY cohort. In total 42% of the participants used any of the predefined drugs whereas percentage of medication used increased from 12% in the pre-motormanifest stage to 81% in the advanced motormanifest stages. A significant effect of antipsychotic use on the Stroop Word Test was found in the early HD stages.

Conclusions: No effect of benzodiazepines, SSRIs, atypical antipsychotics and tetrabenazine on cognitive performance was found. Only the use of antipsychotics had a negative effect on cognitive performance in the early stages and should be considered when designing clinical trials with cognition as clinical endpoint.

Introduction

Huntington's disease (HD) is an autosomal dominant inherited, progressive neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene on chromosome 4¹. HD is characterized by a triad of symptoms: motor abnormalities, behavioral signs and cognitive deterioration². As the exact location of the expanded gene is known, individuals at risk can be tested for the expanded HD gene before any symptoms or signs appear.

Motor abnormalities are the most characteristic signs of HD, but gene-expansion carriers and caregivers perceive cognitive decline and behavioral signs to be the most burdensome^{3, 4}. These can precede motor signs by several years⁵⁻¹³. As cognitive decline starts early and continues as the disease progresses, cognition is recognized as a potential endpoint in clinical trials. Nowadays, a broad range of cognitive domains is evaluated in almost all clinical trials¹⁴, including psychomotor speed which starts to slow down early on and continues to worsen throughout the later HD stages^{15, 16}. It is essential to know which factors could possibly influence cognitive performance in HD in order to evaluate whether potential interventions could stop or slow down cognitive decline in HD.

As there is no cure for HD, medication is prescribed to manage HD symptoms. Many HD gene expansion carriers take psychotropic medication for behavioral and depressive signs; i.e. medication targeting non-cognitive neuropsychiatric signs^{2, 17}. For instance, one study showed that in a European HD population 84% of HD patients received symptomatic treatment¹⁸. Unfortunately, there is only low level of evidence on the effect and side effects of using certain medication in HD, most prescriptions are based on clinical experience^{19, 20}. Depression is common in HD and is often treated with antidepressants with a first choice of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). There is some evidence that some SSRIs might have a positive effect on cognition in the prodromal phase of HD, i.e. before any definite HD symptoms are present²¹. Behavioral symptoms, e.g. anxiety, are often treated with benzodiazepines²⁰. However, the effect of benzodiazepine on cognitive performance in HD is not well documented. We do know from other studies that the higher the intake of benzodiazepines the greater risk of cognitive impairment and in the elderly population it is related to a higher risk of dementia^{22, 23}. In a French study it was shown that also the use of antipsychotics is common in HD and some have a negative effect on cognition²⁴. In another study it was found that HD patients using antipsychotic medication (classical and atypical) or tetrabenazine had a faster disease progression²⁵. By taking these reports together, there is some indication that the use of these types of medication have an impact on cognitive performance on HD.

Some of these studies only evaluated whether using one or few drugs has an effect on cognitive performance, but not the entire medication group was evaluated. But for many clinical trials individuals are not allowed to take any of these drugs because it might influence the outcome measures.

Therefore, the aim of this observational, explorative study is to investigate whether there is a difference in cognitive performance between HD gene-expansion carriers using medication targeting non-cognitive neuropsychiatric signs or tetrabenazine compared to non-users in a clinical HD population. We expect that the SSRI group has the same cognitive performance as non-users. For all other medication groups, we expect that users display a more impaired cognitive performance. This is evaluated in a large HD population seen at several specialized HD clinics throughout Europe, no medication use was adapted for this study.

Methods

Participants

REGISTRY is a European, multicenter, longitudinal, observation study, facilitated by the European Huntington's Disease Network (EHDN). A total of 2,289 confirmed HD gene expansion carriers with a CAG > 39 of the REGISTRY study were included; all completed the cognitive assessment at baseline. Participants without any motor signs, as defined by a total motor score (TMS) of ≤ 5 on the Unified Huntington's Disease Rating Scale (UHDRS)¹⁴, were considered pre-motormanifest. These participants were further divided into 'far from estimated disease onset' (pre-A) and 'close to estimated disease onset' (pre-B), calculated by the Langbehn formula²⁶⁻²⁹ and split at the median of 13.3 years. Participants with unequivocal motor symptoms, TMS >5, were further divided into disease stages based on total functional capacity scale³⁰. The last two disease stages were merged into one due to the small number of participants in these two groups, stages 4 and 5. Ethical approval was obtained for all sites and all participants gave written informed consent. The study was conducted by trained professionals and all data were monitored. For a full description of the study, see Orth et al.³¹.

Assessments

HD gene expansion carriers were assessed for day-to-day functioning, motor, behavior and cognition. The cognitive battery of the Unified Huntington Disease Rating Scale (UHDRS)¹⁴ was used to evaluate cognitive performance: letter verbal

fluency test (total number correct in one minute for three letters; as the study was administered in different countries, the letters also differed by country), Stroop Color-Word-Interference Test: word-reading, color-naming and interference condition (total number correct for each condition in 45 seconds; here the colors are red, blue and green), and the Symbol Digit Modalities Test (total number correct in 90 seconds).

All medications used were recorded in the REGISTRY study. For analysis purposes, participants were grouped as follows: taking benzodiazepines, selective serotonin reuptake inhibitor (SSRI) antidepressants, antipsychotics, atypical antipsychotics or tetrabenazine. For more information on the exact medication taken, see supplementary appendix 1. Participants were allowed to take other medication prescribed for other conditions such as hypertension.

Statistical analysis

To assess whether there were group characteristic differences an ANOVA or, when appropriate, a chi-square test was used.

Univariate general linear model was applied to evaluate whether medication users performed differently on the cognitive tasks than non-medication users during the baseline visit. In this model, medication group and disease stage are added as fixed factors, gender, age, CAG length and years of education as covariates; interaction effect of disease stage and medication use was also added to the model. For the multiple comparison analysis, a conservative significant level was used: $p = 0.05$ divided by the number of tests performed (i.e. $p = 0.002$).

Table 1: Group characteristics

	PreA N=283	PreB N=239	Stage 1 N=712	Stage 2 N=619	Stage 3 N=378	Stage 4+5 N=58
Age ^a	34 (8)	42 (10)	47 (11)	51 (12)	53 (11)	54 (11)
CAG repeat length ^a	42 (2)	44 (3)	44 (3)	44 (3)	44 (3)	45 (4)
Years of education ^a	13 (3)	13 (7)	12 (5)	11 (4)	11 (6)	10 (3)
Sex (Male/Female) ^b	96/187	104/135	384/328	304/315	189/189	20/38

PreA: pre-motormanifest A; PreB: pre-motormanifest B

^aMean (standard deviation)

^bTotal number

Results

The six disease stage groups differed significantly from each other based on: age ($F(5,2283)=139.44$, $p<0.01$), years of education ($F(5,2152)=12.26$, $p<0.01$), CAG repeat length ($F(5,2283)=22.83$, $p<0.01$) and gender ($\chi^2(5) =39.59$; $p<0.01$), see table 1.

In total 58% of the participants did not use any medication. If disease stage was considered, the percentage of participants not taking medication gradually declined from pre-A (88%) to stages 4 and 5 (19%), see table 2. In addition, polypharmacy increased from pre-A (3%) to stages 4 and 5 (48%). About 85% of the medication users were already on medication for at least 2 months with stable doses.

The use of antipsychotics had a significant effect on the results of the Stroop Word Test ($F(1, 1993)=14.9$, $p=0.0001$), suggesting that participants using antipsychotics scored worse on the Stroop Word Test than non-users, see figure 1. Antipsychotics users in group stage 2 and stage 3 scored on average lower than then non-users (mean difference: 13 and 10, respectively). However, this effect disappeared with the interaction effect of all disease stages ($F(4, 1993)=0.47$, $p=0.76$). The use of benzodiazepines, SSRI antidepressants, atypical antipsychotics or tetrabenazine had no effect on cognitive performance on any of the administered tasks.

Discussion

This study shows that about half of the HD-REGISTRY population used medication targeting non-cognitive neuropsychiatric disturbances and/or tetrabenazine. The percentage of HD gene carriers taking these medications increased from pre-motormanifest to the advanced HD. The most logical explanation for this increase throughout the disease stages is that advanced HD individuals have severe symptoms


Table 2: Total number of participants taking medications

	PreA N=283	PreB N=239	Stage 1 N=712	Stage 2 N=619	Stage 3 N=378	Stage 4+5 N=58
No medication ^a	251 (88%)	202 (85%)	463 (65%)	283 (46%)	113 (30%)	11 (19%)
Benzodiazepines ^a	6 (2%)	5 (2%)	23 (3%)	29 (4%)	9 (2%)	2 (3%)
SSRI ^a	16 (6%)	24 (10%)	84 (12%)	78 (13%)	43 (12%)	3 (5%)
Antipsychotics ^a	1 (<1%)	—	8 (1)	10 (2%)	14 (4%)	—
Atypical antipsychotics ^a	1 (<1%)	—	62 (9%)	86 (14%)	66 (17%)	13 (23%)
Tetrabenazine ^a	—	1 (1%)	6 (1%)	13 (2%)	9 (2%)	1 (2%)
Mix ^a	8 (3%)	7 (2%)	66 (9%)	120 (19%)	124 (33%)	28 (48%)

PreA: pre-motormanifest A; PreB: pre-motormanifest B

^aTotal number (%)

Figure 1: Performance on the Stroop Word Test per disease stage and medication group



which need to be managed with medication. In addition, the pre-motormanifest individuals might still benefit from non-pharmacological interventions which should first be explored in treating symptoms²⁰. Throughout disease progression symptoms become more severe, global functioning decreases and medication treatment becomes useful, supported by adjunctive therapies, to manage all symptoms³². Polypharmacy is common in HD due to the complexity of the disease and several symptoms which need to be addressed²⁰ which is supported by our results that about 40% of all medication users used a mix of the pre-defined medication groups.

By evaluating the effect of medication use on cognitive performance, we only found a negative effect of antipsychotic medication on a task measuring psychomotor speed, that is the Stroop Word Test, in the early HD phase. This is an important finding for future clinical trials, especially because the effect was found in the early stages. Future clinical trials will most likely focus on pre-motormanifest and/or early HD gene carriers to evaluate whether treatment influences disease progression in an early

stage of the disease to ensure the highest quality of life for the HD gene carriers. With our findings we would recommend to be cautious to include HD gene carriers using antipsychotic medication if cognition is an important outcome measure of a clinical trial.

Secondly, our study showed that the use of benzodiazepine, SSRI antidepressant, atypical antipsychotic or tetrabenazine has no effect on performance of the UHDRS cognitive battery in the clinical setting. Our finding that tetrabenazine has no effect on cognition is in line with the 80 week open label study of tetrabenazine in HD in which cognitive decline resembled the natural deterioration in HD³³. Regarding future clinical trials targeting cognition in HD, we advise that the use of benzodiazepine, SSRI antidepressant, atypical antipsychotic or tetrabenazine should be allowed if participants are on a stable dose and if there is no suggestion that these medications could have an adverse effect in combination with the investigational drug. This should make it easier to recruit participants for clinical trials as many HD gene carriers use these medications. It also allows to test an investigational drug in a cohort which more closely represents the population seen in clinics, rather than in a strictly pre-defined population and improves the chance to have a successful phase III study.

One of the limitations of this study is that we grouped together the most commonly used medications; i.e. treating slightly different acting agents in the same way. It is possible that one particular drug might have a relatively stronger effect on cognitive performance, but that this effect is masked by grouping several medications together. In addition, we chose to group the medication based on relatively broad categorization as used by the Dutch regulatory agency. These categorization is based on broad pharmacogenetics, we did not create more subgroups based on the mechanic profile of the acting agent. The reason for this is that most studies are based on animal or cell studies but we do not know how all the different acting agents work in the human brain or even in the diseased human brain. It might be of interest for future studies to explore this more extensively. Furthermore, we only looked at whether participants used medication, not at the exact doses taken, although we do know that the majority was on a stable dose. In addition, participants were allowed to take co-medications, such as antihypertensive drugs, combinations which could affect cognitive performance. On a positive note, the REGISTRY database provides an opportunity to look at real-life medication use and its effect on cognitive performance seen at the clinics.

To conclude, antipsychotics have a negative effect on cognitive performance in the early HD stages, whereas benzodiazepines, SSRIs, atypical antipsychotics and tetrabenazine seem to have no effect on cognitive performance in HD.

Acknowledgment list

REGISTRY 2004- 2014

Registry Steering committee: Anne-Catherine Bachoud-Lévi, Anna-Rita Bentivoglio, Ida Biunno, Raphael M. Bonelli, Juliana Bronzova, Jean-Marc Burgunder, Stephen B. Dunnett, Joaquim J. Ferreira, Jan Frich, Joe Giuliano, Olivia J. Handley, Arvid Heiberg, Sergey Illarionov, Torsten Illmann, Jiri Klempir, G. Bernhard Landwehrmeyer, Jamie Levey, Tim McLean, Jørgen E. Nielsen, Susana Pro Koivisto, Markku Päivärinta, Sven Pålhagen, Oliver Quarrell, Maria Ramos-Arroyo, Raymund A.C. Roos, Carsten Saft, Ana Rojo Sebastián, Sarah J. Tabrizi, Wim Vandenberghe, Christine Verellen-Dumoulin, Tereza Uhrova, Jan Wahlström+, Jacek Zaremba

Language coordinators: Verena Baake (formerly Rödiger), Katrin Barth, Monica Bascuñana Garde, Tomás Bernard, Sabrina Betz, Reineke Bos, Adrien Come, Leonor Correia Guedes, Jenny Callaghan, Selene Capodarca, Sébastien Charpentier Wildson, Vieira da Silva, Martina Di Renzo, Daniel Ecker, Ana Maria Finisterra, Ruth Fullam, Camille Genoves, Mette Gilling, Olivia J Handley, Carina Hvalstedt, Christine Held, Kerstin Koppers, Claudia Lamanna, Matilde Laurà, Asunción Martínez Descals, Saul Martinez-Horta, Tiago Mestre, Sara Minster, Daniela Monza, Kristina Münkler, Lisanne Mütze, Martin Oehmen, Helene Padiou, Laurent Paterski, Nadia Peppas, Susana Pro Koivisto, Beate Rindal, Dawn Rogers, Niini Røren (formerly Heinonen), Ana Salgueiro, Pavla Šašinková, Catherine Taylor, Erika Timewell, Jenny Townhill, Patricia Trigo Cubillo, Marleen R van Walsem, Marie-Noelle Witjes-Ané, Grzegorz Witkowski, Abigail Wright, Daniel Zielonka, Eugeniusz Zielonka, Paola Zinzi

AUSTRIA

Graz (Medizinische Universitäts Graz, Psychiatrie): Raphael M. Bonelli, Karen Hecht, Brigitte Herranhof, Anna Holl (formerly Hödl), Hans-Peter Kapfhammer, Michael Koppitz, Sabine Lilek, Markus Magnet, Nicole Müller, Daniela Otti, Annamaria Painold, Karin Reisinger, Monika Scheibl, Helmut Schögl, Jasmin Ullah

Innsbruck (Universitätsklinik Innsbruck, Neurologie): Eva-Maria Braunwarth, Florian Brugger, Lisa Buratti, Eva-Maria Hametner, Caroline Hepperger, Christiane Holas, Anna Hotter, Anna Hussl, Barbara Larcher, Philipp Mahlknecht, Christoph Müller, Bernadette Pinter, Werner Poewe, Eva-Magdalena Reiter, Klaus Seppi, Fabienne Sprenger, Gregor Wenning

Salzburg (Christian-Doppler-Klinik Salzburg, Universitätsklinikum der PMU, Universitätsklinik für Neurologie): Raphael M. Bonelli, Gunther Ladurner, Stefan Lilek, Daniela Sinadinosa, Wolfgang Staffen, Anna Maria Walleczek

BELGIUM

Charleroi (Institut de Pathologie et de Génétique (IPG)): Michel Dupuis, Cécile Minet, Pascale Ribaï, Dominique Van Paemel, Christine Verellen-Dumoulin

CZECH REPUBLIC

Prague (Extrapyramidové centrum, Neurologická klinika, 1. LF UK a VFN): Jiří Klempíř, Veronika Majerová, Jan Roth

FINLAND

Kuopio: Paivi Hartikainen, Mari Ollokainen

Tampere (Terveyystalo Healthcare Service Centre): Maire Santala

Turku-Suvituuli (Rehabilitation Centre Suvituuli): Pia Eklund, Heli Hiivola, Hannele Hyppönen, Kirsti Martikainen, Katri Tuuha

FRANCE

Angers (Centre de référence des maladies neurogénétique- CHU d'Angers): Philippe Allain, Dominique Bonneau, Marie Bost, Bénédicte Gohier, Marie-Anne Guérid, Audrey Olivier, Julie Prouzet, Adriana Prundean, Clarisse Scherer-Gagou, Christophe Verny

Bordeaux (Hôpital Pellegrin): Blandine Babiloni, Sabrina Debruxelles, Charlotte Duché, Cyril Goizet, Laetitia Jameau, Danielle Lafoucrière, Umberto Spampinato

Clermont-Ferrand (Hôpital Gabriel Montpied): Julien Couttier, Bérengère Debilly, Christine Delaigue, Franck Durif, Perrine Legendre, Sylvie Loiseau, Miguel Ulla, Tiphaine Vidal

Creteil (Hôpital Henri Mondor): Anne-Catherine Bachoud-Lévi, Farideh Badei, Marie-Françoise Boissé, Lotfi Boudali, Laurent Cleret de Langavant, Laurie Lemoine, Graca Morgado, Katia Youssouf

Lille-Amiens:

Lille (CHRU Roger Salengro): Agnès Annic, Recka Barthélémy, Christelle De Bruycker, Maryline Cabaret, Anne-Sophie Carette, Nicolas Carrière, Eric Decorte, Luc Defebvre, Marie Delliaux, Arnaud Delval, Alizé Depelchin, Alain Destee, Nelly Dewulf-Pasz, Thibaut Dondaine, Florence Dugauquier, Kathy Dujardin, Lucie Hopes, Pierre Krystkowiak, Marie-Hélène Lemaire, Sylvie Manouvrier, Eugénie Mutez, Mireille Peter, Lucie Plomhause, Bernard Sablonnière, Clémence Simonin, Céline Tard, Stéphanie Thibault-Tanchou, Isabelle Vuillaume

Amiens (CHU Sud): Marcellin Bellonet, Alexandra Benoit, Hassan Berrisoul, Stéphanie Blin, Françoise Courtin, Cécile Duru, Véronique Fasquel, Mélanie Flament, Olivier Godefroy, Pierre Krystkowiak, Béatrice Mantaux, Alicia Playe, Martine Roussel, Mélissa Tir, Béatrice Schüler, Sandrine Wannepain

Marseille (Hôpital La Timone): Jean-Philippe Azulay, Christelle Chabot, Marie Delfini, Alexandre Eusebio, Frédérique Fluchere, Christine Garreau, Hélène Grosjean, Aicha Guenam, Laura Mundler, Marielle Nowak, Rolland Rasetta

Paris (Hôpital de la Pitié Salpêtrière): Sandra Benaich, Alexis Brice, Sarah Boster, Perrine Charles, Alexandra Durr, Claire Ewencyk, Hélène Francisque, Céline Jauffret, Damian Justo, Abdulrahman Kassar, Stephan Klebe, Fabien Lesne, Paolo Milani, Marie-Lorraine Monin, Emmanuel Roze, Alina Tataru, Maya Tchikviladzé

Rouen (Hôpital Charles Nicolle): Sandrine Bioux, Evangeline Bliaux, Carole Girard, Lucie Guyant-Maréchal, Didier Hannequin, Véronique Hannier, Séverine Jourdain, David Maltête, Dorothée Pouliquen

Strasbourg (Hôpital Civil): Mathieu Anheim, Nadia Barun, Ouhaïd Lagha-Boukbiza, Nadine Longato, Christophe Marcel, Clélie Phillipps, Gabrielle Rudolf, Gisèle Steinmetz, Christine Tranchant, Caroline Wagner, Marie-Agathe Zimmermann

Toulouse (Hôpital Purpan): Leily Blondeau, Fabienne Calvas, Samia Cheriet, Helène Delabaere, Jean-François Demonet, Jérémie Pariente, Michèle Pierre, Sandrine Rolland

GERMANY

Aachen (Universitätsklinikum Aachen, Neurologische Klinik): Christoph Michael Kosinski, Eva Milkereit, Daniela Probst, Kathrin Reetz, Christian Sass, Johannes Schiefer, Christiane Schlangen, Cornelius J. Werner

Berlin (Universitätsmedizin Berlin, Klinik und Poliklinik für Neurologie): Markus Beuth, Harald Gelderblom, Josef Priller, Harald Prüß, Eike Spruth, Silvia Thiel

Bochum (Huntington-Zentrum (NRW) Bochum im St. Josef-Hospital): Jürgen Andrich, Gisa Ellrichmann, Lennard Herrmann, Rainer Hoffmann, Barbara Kaminski, Peter Kraus, Carsten Saft, Christiane Stamm

Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang): Herwig Lange, Robert Maiwald

Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik für Neurologie): Cecile Bosredon, Ulrike Hunger, Matthias Löhle, Antonia Maass, Christiana Ossig, Simone Schmidt, Alexander Storch, Annett Wolz, Martin Wolz

Erlangen (Universitätsklinikum Erlangen, Molekulare Neurologie und Klinik für Neurologie): Zacharias Kohl, Christina Kozay, Jasmin Ullah, Jürgen Winkler

Freiburg (Universitätsklinik Freiburg, Neurologie): Ulrike Bergmann, Regina Böringer, Philipp Capetian, Gerit Kammel, Johann Lambeck, Miriam Mächtel, Simone Meier, Michel Rijntjes, Birgit Zucker

Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie): Kai Boelmans, Christos Ganos, Ines Goerendt, Walburgis Heinicke, Ute Hidding, Jan Lewerenz, Alexander Münchau, Michael Orth, Jenny Schmalfeld, Lars Stubbe, Simone Zittel

Hannover (Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover): Gabriele Diercks, Dirk Dressler, Flverly Francis, Sabine Gayde-Stephan, Heike Gorzolla, Bianca Kramer, Rebecca Minschke, Christoph Schrader, Pawel Tacik

Itzehoe (Schwerpunktpraxis Huntington, Neurologie und Psychiatrie): Michael Ribbat+

Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd): Bernhard Longinus

Marburg UNI (Universitätsklinik Marburg, Sprechstunde für choreatiforme Bewegungsstörungen): Carsten Möller, Katrin Birk

München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der Neurologischen Klinik und Poliklinik der Technischen Universität München): Antje Lüsebrink, Mark Mühlau, Alexander Peinemann, Michael Städtler, Adolf Weindl, Juliane Winkelmann, Cornelia Ziegler

Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie): Natalie Bechtel, Heike Beckmann, Stefan Bohlen, Nicole Göpfert, Eva Hölzner, Herwig Lange, Ralf Reilmann, Stefanie Rohm, Silke Rumpf, Christian Sass, Sigrun Schepers, Nathalia Weber

Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils)): Michael Bachmeier, Matthias Dose, Nina Hofstetter, Ralf Marquard, Alzbeta Mühlbäck

Ulm (Universitätsklinikum Ulm, Neurologie): Katrin Barth, Andrea Buck, Julia Connemann, Daniel Ecker, Carolin Geitner, Christine Held, Andrea Kesse, Bernhard Landwehrmeyer, Franziska Lezius, Jan Lewerenz, Solveig Nepper, Anke Niess, Michael Orth, Ariane Schneider, Daniela Schwenk, Sigurd Süßmuth, Sonja Trautmann, Melanie Vogel, Patrick Weydt

ITALY

Bari (Neurophysiopathology of Pain Unit, Basic Medical, Neuroscience and Sensory System Department, University of Bari): Claudia Cormio, Olimpia Difruscolo, Giovanni Franco, Vittorio Sciruicchio, Claudia Serpino, Marina de Tommaso

Bologna (DIBINEM - Alma Mater Studiorum - Università di Bologna, IRCCS Istituto delle Scienze Neurologiche di Bologna): Giovanna Calandra-Buonaura, Sabina Capellari, Pietro Cortelli, Roberto Gallassi, Roberto Poda, Cesa Scaglione

Florence (Department of Neuroscience, University of Florence & Careggi University Hospital): Elisabetta Bertini, Caterina Bartoli, Fernanda Fortunato, Elena Ghelli, Andrea Ginestroni, Claudia Mechi, Marco Paganini, Silvia Piacentini, Silvia Pradella, Anna Maria Romoli, Sandro Sorbi

Genoa (Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova): Giovanni Abbruzzese, Monica Bandettini di Poggio, Giovanna Ferrandes, Paola Mandich, Roberta Marchese, Emilio Di Maria

Milan (SODS Genetica delle Malattie Neurodegenerative e Metaboliche & U.O. Neurologia, Fondazione IRCCS Istituto Neurologico Carlo Besta): Alberto Albanese, Simona Castagliuolo, Anna Castaldo, Stefano Di Donato, Daniela Di Bella, Cinzia Gellera, Silvia Genitrini, Caterina Mariotti, Daniela Monza, Lorenzo Nanetti, Marta Panzeri, Dominga Paridi, Paola Soliveri, Francesca Spagnolo, Franco Taroni, Chiara Tomasello

Naples (Department of Neurosciences and Reproductive and Odontostomatological Sciences, Federico II University of Naples): Giuseppe De Michele, Luigi Di Maio, Carlo Rinaldi, Marco Massarelli, Silvio Peluso, Alessandro Roca, Cinzia Valeria Russo, Elena Salvatore, Pierpaolo Sorrentino, Tecla Tucci

Pozzilli (IS) (IRCCS Neuromed): Milena Cannella, Valentina Codella, Francesca De Gregorio, Annunziata De Nicola, Francesca Elifani, Tiziana Martino, Francesca Lovo, Irene Mazzante, Martina Petrollini, Maria Simonelli, Ferdinando Squitieri, Maurizio Vezza

Rome (LIRH Foundation): Barbara D'Alessio, Chiara Esposito, Irene Mazzante, Ferdinando Squitieri

Rome (Department of Neurology, Università Cattolica del Sacro Cuore; Institute of Translational Pharmacology & Institute of Cognitive Sciences and Technologies, National Research Council of Italy): Anna Rita Bentivoglio, Francesco Bove, Claudio Catalli, Raffaella Di Giacomo, Alfonso Fasano, Marina Frontali, Arianna Guidubaldi, Tamara Ialongo, Gioia Jacopini, Giovanna Loria, Anna Modoni, Martina Petracca, Carla Piano, Piccininni Chiara, Davide Quaranta, Silvia Romano, Francesco Soleti, Marcella Solito, Maria Spadaro, Flavia Torlizzi, Paola Zinzi

Rome (Azienda Ospedaliera Sant'Andrea; Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome; Institute of Translational Pharmacology & Institute of Cognitive Sciences and Technologies, National Research Council of Italy): Giulia Coarelli, Michela Ferraldeschi, Marina Frontali, Gioia Jacopini, Giovanni Ristori, Silvia Romano, Paola Zinzi

NETHERLANDS

Enschede (Medisch Spectrum Twente): Monique S.E. van Hout, Jeroen P.P. van Vugt, A. Marit de Weert, Marloes Verhoeven

Groningen (Polikliniek Neurologie): Meike Dekker, Nico Leenders, Joost van Oostrom, Jesper Klooster, Berry Kremer

Leiden (Leiden University Medical Centre (LUMC)): Verena Baake, Simon J. A. van den Bogaard, Reineke Bos, Eve M. Dumas, Ellen P. 't Hart, Anne Kampstra, Raymund A.C. Roos, Anne Schoonderbeek

Maastricht: Annelien Duits, Mayke Oosterloo, Mirella Waber

NORWAY

Bergen (Haukeland University Hospital, Dept of Medical Genetics and Olaviken Psychiatric Hospital): Ellen Økland Blinkenberg. (NKS Olaviken`s HD clinic): Erik Hauge, Hilde Tyvoll

Oslo University Hospital (Dept. of Medical Genetics, Dept. of Neurology, Dept. of Neurorehabilitation): Olaf Aaserud, Nils Olaf Aanonsen, Kathrine Bjørge, Nancy Borgeød, Elisabeth Dramstad, Madeleine Fannemel, Jan C. Frich, Per F. Gørvell, Kathrine Haggag, Cecilie

Haggag Johannessen, Arvid Heiberg, Lars Retterstøl, Oddveig Røsby, Jutta Rummel, Alma Sikiric, Bodil Stokke, Marleen van Walsem, Ragnhild Wehus

Trondheim (St. Olavs Hospital): Inga Bjørnevoll, Sigrid Botne Sando, Marte Gjøel Haug, Hanna Haugan Størseth, Vibeke Arntsen

POLAND

Gdansk (St. Adalbert Hospital, Gdansk, Medical University of Gdansk, Neurological and Psychiatric Nursing Dpt.): Artur Dziadkiewicz, Agnieszka Konkel, Ewa Narożańska, Małgorzata Nowak, Piotr Robowski, Emilia Sitek, Jarosław Slawek, Witold Soltan, Michał Szinwelski

Katowice (Medical University of Silesia, Katowice): Michał Arkuszewski, Magdalena Błaszczyk, Magdalena Boczarska-Jedynak, Ewelina Ciach-Wysocka, Agnieszka Gorzkowska, Barbara Jasińska-Myga, Aleksandra Kaczmarczyk, Gabriela Kłodowska – Duda, Grzegorz Opala, Monika Rudzińska, Daniel Stempel

Krakow (Krakowska Akademia Neurologii): Krzysztof Banaszkiwicz, Dorota Boćwińska, Kamila Bojakowska-Jaremek, Małgorzata Dec, Natalia Grabska, Małgorzata Krawczyk, Ewelina Kubowicz, Michalina Malec-Litwinowicz, Monika Rudzińska, Agata Stenwak, Andrzej Szczudlik, Elżbieta Szczygieł, Magdalena Wójcik, Anna Wasielewska

Poznan (Poznan University of Medical Sciences, Poland): Jacek Anioła Anna Bryl, Anna Ciesielska, Aneta Klimberg, Jerzy Marcinkowski, Husam Samara, Justyna Sempołowicz, Bartłomiej Wiśniewski, Daniel Zielonka

Warsaw-MU (Medical University of Warsaw, Neurology): Anna Gogol (formerly Kalbarczyk), Piotr Janik, Zygmunt Jamrozik, Anna Kaminska, Hubert Kwiecinski+, Natalia Szejko

Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, First Dep. of Neurology): Jakub Antczak, Katarzyna Jachinska, Wioletta Krysa, Maryla Rakowicz, Przemysław Richter, Rafał Rola, Danuta Ryglewicz, Halina Sienkiewicz-Jarosz, Iwona Stępnia, Anna Sulek, Grzegorz Witkowski, Jacek Zaremba, Elżbieta Zdżienicka, Karolina Ziara-Jakutowicz

PORTUGAL

Coimbra – (Hospital Universitário de Coimbra): Cristina Januário, Filipa Júlio

Lisbon-HSM (Hospital de Santa Maria, Clinical Pharmacology Unit, Instituto de Medicina Molecular): Leonor Correia Guedes, Miguel Coelho, Joaquim J Ferreira, Tiago Mestre, Tiago Mendes, Anabela Valadas

Porto-HGSA (Hospital Santo António- Centro Hospitalar do Porto): Gonçalo Cação, Sara Cavaco, Joana Damásio, Joana Fernandes, Rui Loureiro, Inês Moreira, Marina Magalhães,

Porto- HSJ (Hospital de São João): Carlos Andrade, Andreia Costa, Carolina Garrett, Miguel Gago, Joana Guimarães, João Massano, Joana Meireles, Ana Monteiro

SPAIN

Badajoz (Hospital Infanta Cristina): Carmen Durán Herrera, Patrocinio Garcia Moreno

Barcelona-Bellvitge (Hospital Universitari de Bellvitge): Jordi Bas, Núria Busquets, Matilde Calopa, Serge Jaumà Classen, Nadia Rodríguez Dedichá

Barcelona- Clínic i Provincial (Hospital Clínic i Provincial): María Teresa Buongiorno, Andrés de la Cerda Santa María, Esteban Muñoz, Pilar Santacruz

Barcelona-Hospital Mútua de Terrassa: Miquel Aguilar Barbera, Ana Rojo Sebastián, Sonia Arribas Pardo, Dolors Badenes Guia, Noemi Calzado, Laura Casas Hernanz, Juan Pablo Tartari Díaz-Zorita, Judit López Catena, Pilar Quiléz Ferrer, Gemma Tome Carruesco

Barcelona-Merced (Hospital Mare de Deu de La Merced): Misericordia Floriach Robert, Cèlia Mareca Viladrich, Elvira Roca, Jesús Miguel Ruiz Idiago, Antonio Villa Riballo

Barcelona-Santa Cruz y San Pablo (Hospital de la Santa Creu i Sant Pau): Antonia Campolongo, Ramon Fernandez de Bobadilla, Jaime Kulisevsky Bojarsky, Saul Martinez-Horta, Javier Pagonabarraga, Jesus Perez Perez, Roser Ribosa, Carolina Villa

Burgos (Servicio de Neurología Hospital General Yagüe): Esther Cubo, Cecilia Gil Polo, Natividad Mariscal

Canarias (Hospital Insular de Gran Canaria): Sandra Gutierrez Romero, José Matías Arbelo, Rocío Malo de Molina, Idaira Martín, Juan Manuel Periañez, Beatriz Udaeta

Fuenlabrada (Hospital Universitario): Fernando Alonso-Frech, María del Valle Loarte

Granada (Hospital Universitario San Cecilio, Neurología): Francisco Barrero, Blas Morales

Madrid-BTCIEN (Fundación CIEN): Belén Frades, Marina Ávila Villanueva, Maria Ascension Zea Sevilla

Madrid-Clinico (Hospital Clínico Universitario San Carlos): Fernando Alonso Frech, María del Mar Fenollar, Rocío García-Ramos García, Clara Villanueva

Madrid RYC (Hospital Ramón y Cajal, Neurología): Mónica Bascuñana, Marta Fatás Ventura, Juan García Caldentey, Guillermo García Ribas, Justo García de Yébenes, José Luis López-Sendón Moreno, Verónica Mañanes Barral, Patricia Trigo Cubillo

Madrid FJD (Madrid-Fundación Jiménez Díaz): Cici Feliz Feliz, Pedro José García Ruíz, Ana García, Juan García Caldentey, Rosa Guerrero López, Antonio Herranz Bárcenas, Asunción Martínez-Descals, Veronica Puertas Martin, Noelia Rodríguez Martínez, María José Sainz Artiga, Vicenta Sánchez, Angel Martínez Pueyo, Javier del Val Fernandez

Murcia (Hospital Universitario Virgen de la Arrixaca): Moreau María Dolores Alarcón, Carmen Antúnez Almagro, Esther Diéguez, Lorenza Fortuna, Salvadora Manzanares, Juan Marín Muñoz, María Martirio Antequera Torres, Fuensanta Noguera Perea, Laura Vivancos

Oviedo (Hospital Central de Asturias): Sonia González, Luis Menéndez Guisasola, Marta Para Prieto, René Ribacoba, Carlos Salvador, Pablo Sánchez Lozano

Palma de Mallorca (Hospital Universitario Son Espases): Juan García Caldentey, Aránzazu Gorospe, Inés Legarda Ramirez, Penelope Navas Arques, Monica Rodriguez Lopera, Barbara Vives Pastor

Pamplona (Complejo Hospitalario de Navarra): Itziar Gaston, Fermin Garcia-Amigot, Maria Dolores Martinez-Jaurrieta, Maria Antonia Ramos-Arroyo

Sevilla (Hospital Virgen Macarena): Fátima Damas Hermoso, José Manuel García Moreno, Carolina Mendez Lucena, Eva María Pacheco Cortegana, José Chacón Peña, Luis Redondo, Violeta Sánchez Sánchez

Valencia (Hospital la Fe): Maria Bosca, Juan Andres Burguera, Francisco Castera Brugada Carmen Peiró Vilaplana, Pilar Solís, Begoña Jeweinat Figuerola, Paloma Millan Palanca

SWEDEN

Göteborg (Sahlgrenska University Hospital): Maria Berglund, Peter Berglund, Radu Constantinescu, Gunnel Fredlund, Ulrika Høsterey-Ugander, Kajsa Lewin, Petra Linnsand, Liselotte Neleborn-Lingefjärd, Jan Wahlström+

Lunds University Hospital: Åsa Petersén, Jan Reimer, Håkan Widner

Umeå (Umeå University Hospital): Måns Berglund, Ghada Loutfi, Carina Olofsson, Eva-Lena Stattin, Laila Westman, Birgitta Wikström

Uppsala University Hospital: Camilla Ekwall, Marie-Lousie Göller, Valter Niemelä, Jimmy Sundblom

SWITZERLAND

Bern: Jean-Marc Burgunder, Yanik Stebler (Swiss HD Zentrum), Alain Kaelin, Irene Romero, Michael Schüpbach, Sabine Weber Zaugg (Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, Universität Bern)

Zürich (University Hospital and University of Zurich): Hans H. Jung, Jens A. Petersen, Maria Ligon-Auer, Violeta Mihaylova

U.K.

Aberdeen (NHS Grampian Clinical Genetics Centre & University of Aberdeen): Lorna Downie, Roisin Jack, Kirsty Matheson, Zosia Miedzybrodzka, Daniela Rae, Sheila A Simpson, Fiona Summers, Alexandra Ure, Vivien Vaughan

Birmingham (The Barberrry Centre, Dept of Psychiatry): Shahbana Akhtar, Jenny Crooks, Adrienne Curtis, Jenny de Souza (Keylock), John Piedad, Hugh Rickards, Jan Wright

Bristol (North Bristol NHs Trust, Southmead hospital): Elizabeth Coulthard, Louise Gethin, Beverley Hayward, Kasia Sieradzan, Abigail Wright

Cambridge (Cambridge Centre for Brain Repair, Forvie Site): Roger A. Barker, Deidre O'Keefe, Anna Gerrtiz (nee Di Pietro), Kate Fisher, Anna Goodman, Susan Hill, Sarah Mason, Rachel Swain, Natalie Valle Guzman

Cardiff (Schools of Medicine and Biosciences, Cardiff University): Monica Busse, Cynthia Butcher, Stephen Dunnett, Catherine Clenaghan, Ruth Fullam, Sarah Hunt, Lesley Jones, Una Jones, Hanan Khalil, Sara Minster, Michael Owen, Kathleen Price, Jenny Townhill, Anne Rosser

Dundee (Scottish Huntington’s Association, Ninewells Hospital): David Goudie, Lindsay Buchanan, Paula McFadyen, Alison Tonner, Anne-Marie Taylor

Edinburgh (SE Scotland Genetic Service, Western General Hospital): Maureen Edwards, Carrie Ho (Scottish Huntington’s Association), Marie McGill, Mary Porteous, Pauline Pearson

Exeter (Department of Neurology Royal Devon and Exeter Foundation Trust Hospital): Timothy Harrower, Sarah Irvine

Fife (Scottish Huntington’s Association Whyteman’s Brae Hospital): Peter Brockie, Jillian Foster, Nicola Johns, Sue McKenzie, Jean Rothery, Gareth Thomas, Shona Yates

Glasgow (Glasgow HD Management Clinic, Southern General Hospital): Catherine Deith, Jane Ireland, Stuart Ritchie

Gloucester (Department of Neurology Gloucestershire Royal Hospital): Pauline Brown, Liz Burrows, Amy Fletcher, Alison Harding, Fiona Laver, Mark Silva, Aileen Thomson

Hull (Castle Hill Hospital): Carol Chu, Carole Evans, Deena Gallantree, Stephanie Hamer, Alison Kraus, Ivana Markova, Ashok Raman

Leeds (Chapel Allerton Hospital, Department of Clinical Genetics): Jeremy Cosgrove, Deena Gallantree, Stephanie Hamer, Emma Hobson, Stuart Jamieson, Alison Kraus, Mandy Longthorpe, Ivana Markova, Hannah Musgrave, Caroline Peacy, Ashok Raman, Liz Rowett, Jean Toscano, Sue Wild, Pam Yardumian

Leicester (Leicestershire Partnership Trust, Mill Lodge): Carole Clayton, Heather Dipple, Dawn Freire-Patino, Caroline Hallam, Julia Middleton

London (St. Georges-Hospital): Uruj Anjum, Jan Coebergh, Charlotte Eddy, Nayana Lahiri, Meriel McEntagart, Michael Patton, Maria Peterson, Sarah Rose

London (Guy’s Hospital): Thomasin Andrews, Andrew Dougherty, Charlotte Golding, Fred Kavalier, Hana Laing, Alison Lashwood, Dene Robertson, Deborah Ruddy, Alastair Santhouse, Anna Whaite

London (The National Hospital for Neurology and Neurosurgery): Thomasin Andrews, Stefanie Brown, Stefania Bruno, Elvina Chu, Karen Doherty, Charlotte Golding, Salman Haider, Davina Hensman, Nayana Lahiri, Monica Lewis, Marianne Novak, Aakta Patel, Nicola Robertson, Elisabeth Rosser, Sarah Tabrizi, Rachel Taylor, Thomas Warner, Edward Wild

Manchester (Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust): Natalie Arran, Judith Bek, Jenny Callaghan, David Craufurd, Ruth Fullam, Marianne Hare, Liz Howard, Susan Huson, Liz Johnson, Mary Jones, Ashok Krishnamoorthy, Helen Murphy, Emma Oughton, Lucy Partington-Jones, Dawn Rogers, Andrea Sollom, Julie Snowden, Cheryl Stopford, Jennifer Thompson, Iris Trender-Gerhard, Nichola Verstraelen (formerly Ritchie), Leann Westmoreland

Newcastle-upon-Tyne (Centre for Life, Institute of Medical Genetics): Ginette Cass, Lynn Davidson, Jill Davison, Neil Fullerton, Katrina Holmes, Suresh Komati, Sharon McDonnell, Zeid Mohammed, Karen Morgan, Lois Savage, Baldev Singh, Josh Wood

Northampton (St Andrew’s Healthcare): Elvina Chu, Caroline Knight, Mari O’Neill, Debasish Das Purkayastha

Oxford (Oxford University Hospitals NHS Trust, Dept. of Neurosciences, University of Oxford): Andrea H Nemeth, Gill Siuda, Ruth Valentine, Kathryn Dixon, Richard Armstrong

Plymouth (Plymouth Huntington Disease Service, Mount Gould Hospital): David Harrison, Max Hughes, Sandra Large, John O Donovan, Amy Palmer, Andrew Parkinson, Beverley Soltysiak, Leanne Timings, Josh Williams

Preston (Neurology Department, Preston Royal Hospital): Marianne Hare, Tahir Majeed, Nicola Verstraelen (Ritchie)

Sheffield (The Royal Hallamshire Hospital– Sheffield Children’s Hospital): Oliver Bandmann, Alyson Bradbury, Helen Fairtlough, Kay Fillingham, Isabella Foustanos, Paul Gill, Mbombe Kazoka, Kirsty O’Donovan, Louise Nevitt, Nadia Peppas, Oliver Quarrell, Cat Taylor, Katherine Tidswell, Kirsty O’Donovan

Swindon (Victoria Centre, Great Western Hospital): Lesley Gowers, Kingsley Powell, Pamela Bethwaite, Rachel Edwards, Kathleen Fuller, Michelle Phillips

EHDN’s associate site in Singapore:

National Neuroscience Institute Singapore: Louis Tan, Jean-Marc Burgunder, Puay Ngoh Lau, Emmanuel Pica

References

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell* 1993;72:971-983.
2. Roos RA. Huntington's disease: a clinical review. *OrphanetJRareDis* 2010;5:40.
3. Nehl C, Paulsen JS, Huntington Study G. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. *J Nerv Ment Dis* 2004;192:72-74.
4. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. *Movement disorders : official journal of the Movement Disorder Society* 2008;23:721-726.
5. Duff K, Paulsen J, Mills J, et al. Mild cognitive impairment in prediagnosed Huntington disease. *Neurology* 2010;75:500-507.
6. Kirkwood SC, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. *JNeurolNeurosurgPsychiatry* 2000;69:773-779.
7. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandebussche E, Dom R. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. *Acta NeurolScand* 2002;106:131-141.
8. Paulsen JS, Smith MM, Long JD, investigators PH, Coordinators of the Huntington Study G. Cognitive decline in prodromal Huntington Disease: implications for clinical trials. *J Neurol Neurosurg Psychiatry* 2013;84:1233-1239.
9. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. *JNeurolNeurosurgPsychiatry* 2012;83:687-694.
10. Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA. A review of cognition in Huntington's disease. *Frontiers in bioscience (Scholar edition)* 2013;5:1-18.
11. Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. *JNeuropsychiatry ClinNeurosci* 2012;24:53-60.
12. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. *JNeuropsychiatry ClinNeurosci* 2007;19:441-448.
13. Baake V, Reijntjes R, Dumas EM, Thompson JC, Network RIotEHsD, Roos RAC. Cognitive decline in Huntington's disease expansion gene carriers. *Cortex* 2017;95:51-62.
14. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. *Mov Disord* 1996;11:136-142.
15. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. *Current neurology and neuroscience reports* 2011;11:474-483.

16. Solomon AC, Stout JC, Weaver M, et al. Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. *Mov Disord* 2008;23:1830-1836.
17. Killoran A, Biglan KM. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? *Movement disorders : official journal of the Movement Disorder Society* 2014;29:1404-1413.
18. Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. *Mov Disord* 2008;23:1788.
19. van Duijn E. Treatment of Irritability in Huntington's Disease. *Curr Treat Options Neurol* 2010;12:424-433.
20. van Duijn E. Medical treatment of behavioral manifestations of Huntington disease. *Handb Clin Neurol* 2017;144:129-139.
21. Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. *Mov Disord* 1997;12:397-401.
22. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. *CNS Drugs* 2004;18:37-48.
23. Islam MM, Iqbal U, Walther B, et al. Benzodiazepine Use and Risk of Dementia in the Elderly Population: A Systematic Review and Meta-Analysis. *Neuroepidemiology* 2016;47:181-191.
24. Desamericq G, Dolbeau G, Verny C, et al. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. *PLoS One* 2014;9:e85430.
25. Tedroff J, Waters S, Barker RA, Roos R, Squitieri F, Group ERS. Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. *J Huntingtons Dis* 2015;4:131-140.
26. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. *ClinGenet* 2004;65:267-277.
27. Langbehn DR, Hayden MR, Paulsen JS, Group P-HIoHS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2010;153B:397-408.
28. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurol* 2009;8:791-801.
29. Wild EJ. Huntington's disease conditional onset probability calculator [online]. Available at: <http://edwild.com/205-huntingtons-disease-conditional-onset-probability-calculator/>.
30. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. *Neurology* 1979;29:1-3.
31. Orth M, Handley OJ, Schwenke C, et al. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. *JNeurolNeurosurgPsychiatry* 2011;82:1409-1412.

32. Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease. *PLoS Curr* 2011;3:RRN1260.
33. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. *BMC Neurol* 2009;9:62.

Supplementary Appendix

Medications included in the different groups

Benzodiazepines: Alprazolam, Bromazepam, Brotizolam, Chlordiazepoxide, Clobazam, Clorazepate, Diazepam, Estazolam, Etizolam, Flurazepam, Loprazolam, Lorazepam, Lormetazepam, Midazolam, Nitrazepam, Oxazepam, Prazepam, Temazepam, Zolpidem, Zopiclone

SSRI Antidepressants: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline

Antipsychotics: Amisulpride, Chlorprothixene, Fluphenazine, Flupentixol, Fluspirilene, Haloperidol, Perphenazine, Pimozide, Pipamperone, Sulpiride, Thioridazine, Tiapride, Zuclopenthixol

Atypical antipsychotics: Aripiprazole, Clozapine, Melperone, Olanzapine, Quetiapine, Risperidone

Tetrabenazine

